News

UCB: new pilot plant in Belgium
Enlarge image

BusinessBelgiumSwitzerland

UCB: new pilot plant in Belgium

18.09.2012 - UCB S.A. has officially opened the doors to a new pilot biotech plant at its Braine-L'Alleud site in Belgium.

The Brussels-based drugmaker has invested more than €65m into the project, which was supported by the Walloon region. The 5,100 square meter facility is currently undergoing a validation phase. After becoming fully operational in the course of 2013, the first four bioreactors with a total volume of 3,200 litres will start to produce cell culture-based therapeutic proteins for UCB’s research pipeline and clinical trials. At the same time, manufacturing processes will be designed and optimised to move from development to full scale industrial production. The facility will include integrated laboratories and additional infrastructure to house 100 staff.

“Today, 33% of drugs for human use worldwide are of biotechnological origin and represent more than half of UCB’s current R&D pipeline“, stated Roch Doliveux, CEO of UCB. “With this bio pilot plant, we can more rapidly initiate clinical studies of new antibody-based therapeutics that are addressing serious unmet medical needs.”

 UCB is currently heavily investing to push its production capabilities. Just last year, the Belgian company also initiated a project to build in-house biotech microbial manufacturing capacity in Bulle, Switzerland. The new manufacturing unit is expected to become operational in 2015 and requires an investment of €250m.

© eurobiotechnews.eu/bk

http://www.european-biotechnology-news.com/news/news/2012-03/ucb-new-pilot-plant-in-belgium.html

ResearchUKSwitzerlandItaly

29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.

BusinessGermany

24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

BusinessEUGermanyUK

15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.

ResearchEUGermanyUK

13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.

BusinessFrance

11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.

ResearchSwedenGermany

08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.

ResearchSwitzerlandDenmark

06.08.2014 Roche is re-expanding its involvement in RNAi technologies. The Swiss pharmaceutical company will pay up to €335m for the acquisition of the Danish company Santaris Pharma A/S.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • WILEX2.40 EUR6.67%
  • SANTHERA100.10 CHF1.78%
  • ACTELION112.70 CHF1.35%

FLOP

  • THERAMETRICS0.07 CHF-12.50%
  • VITA 343.70 EUR-5.85%
  • EVOTEC3.68 EUR-1.60%

TOP

  • SANTHERA100.10 CHF67.1%
  • BB BIOTECH142.65 EUR10.2%
  • MAGFORCE6.80 EUR6.1%

FLOP

  • MOLOGEN7.31 EUR-14.0%
  • THERAMETRICS0.07 CHF-12.5%
  • VITA 343.70 EUR-11.1%

TOP

  • SANTHERA100.10 CHF4388.8%
  • CO.DON2.51 EUR213.7%
  • PAION2.43 EUR173.0%

FLOP

  • CYTOS0.25 CHF-93.7%
  • MEDIGENE4.53 EUR-67.5%
  • THERAMETRICS0.07 CHF-53.3%

No liability assumed, Date: 31.08.2014